The abstract is read at the publisher; the summary is JClub's.
In previously treated, RAS-mutant metastatic pancreatic adenocarcinoma, daraxonrasib monotherapy resistance in circulating tumor DNA is linked to RAS-pathway reactivation, seen in 59% of 44 patients.
- Why it matters: Resistance limits durable benefit from RAS(ON) inhibition in PDAC, and the field needs actionable mechanisms to design rational combinations rather than empiric switching.
- What they did: Paired pretreatment and end-of-treatment circulating tumor DNA from 44 phase 1/2 patients was profiled by targeted sequencing of over 800 genes to identify treatment-emergent alterations.
- The result: Treatment-emergent changes affected KRAS amplifications in 36% (16 of 44) and other RAS-pathway nodes (MAPK 25%, RTK 9%, PI3K 9%), with no acquired secondary KRAS mutations; preclinical PDAC models showed concordant drivers and combinations with DNA damage response agents, RTK targeting, or zoldonrasib averted resistance.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
- 2 cited this week
- Open access